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Abstract: Antimitotics binding at the colchicine site of tubulin are important antitumour and vascular disrupting agents. Pyridines 
and azines are privileged scaffolds in medicinal chemistry and in recent years many colchicine site ligands (CSL) have 
incorporated them into their structures with the aim of improving their pharmacokinetic and pharmacodynamics properties. CSL 
have been classified according to their chemical structures and the chemical structures of the pyridine and azine containing 
antimitotic compounds are described. The design principles behind the structural modifications and the achieved effect on the 
biological activity upon inclusion of these heterocycles are also discussed. Lessons from the achievements and failures have been 
extracted and future perspectives delineated. 
 




The discovery of the antitumour activity of the Vinca alkaloids[1] and the subsequent establishment of the inhibition of 
microtubule polymerization as their molecular mechanism of action[2] marked the beginning of modern anticancer 
chemotherapy[3] with the use of combination regimens[4]. This finding put the microtubular system at the centre of attention of 
anticancer chemotherapy, initiating the search for so called antimitotics due to their effect on cell division (Fig. 1). The discovery 
of the tubulin stabilizing taxanes by scientists at the NCI[5, 6] and the difficulty they present in their development as drugs against 
solid tumours[7, 8] once again highlighted the therapeutic potential of tubulin interfering agents. Colchicine (3), a natural product 
from the meadow saffron (Colchicum autumnale), had already played an important role in the discovery of tubulin[9] and was 
soon followed by structurally related natural products binding at the same site of tubulin, such as podophyllotoxin (4)[10] and 
the combretastatins,[11] all of them acting as tubulin polymerization inhibitors (TPI). Compared to the taxanes and the Vinca 
alkaloids, already in clinical use, the ligands binding at the colchicine site have much simpler chemical structures and have 
therefore been the subject of many synthetic medicinal chemistry programs.[12] Although to date, none of them have yet reached 
the market.[13]  
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2: Paclitaxel (Taxol®)1: Vincristine
 
Fig. (1). Structures of tubulin ligands with historical importance 
 
Table 1. State of the Clinical Trials of CSL 






















Withdrawn. Phase II trials for metastatic renal cell carcinoma and 







Withdrawn. Completed Phase II trials but not effective enough for Phase 
III 
Combretastatin A-4P 









Completed. Phase II for advanced anaplastic thyroid cancer.[14] 
Completed. Phase II for advanced solid tumours.[15] 
Completed. Phase II for non-small cell lung cancer. 
Ongoing. Phase II/III for platinum resistant ovarian cancer. 















Completed. Phase I for hepatic tumour. 













Completed. Phase III for advanced-stage soft tissue sarcoma after failure of 
anthracycline and ifosfamide chemotherapies. 
Completed. Phase I for advanced solid tumours.[16] 
Completed. Phase II for recurrent ovarian cancer. 
Completed. Phase II for non-small cell lung cancer. 









Completed. Phase I/II for glioblastoma multiforme.[17] 
Completed. Phase I/II for metastatic melanoma. 
























Completed. Phase I/II for advanced non-small cell lung cancer. 
Recruiting. Phase III for non-small cell lung cancer. 







Completed. Phase I/II for metastatic breast cancer. 









Ongoing. Phase II for children with recurrent neuroblastoma. 
Completed. Phase I/II for non-small cell lung cancer.[18] 
Completed. Phase I/II for advanced lung cancer.[19] It did not show 
efficacy. 
Completed. Phase I/II for metastatic prostate cancer. The treatment was 
not effective. 
Completed: Phase II for colorectal cancer. 
Completed: Phase II for renal cancer. 
Completed. Phase I for refractory solid tumours in young patients.[20] 


























Withdrawn. Phase I/II for partially platinum sensitive ovarian cancer 
patients. Phase I completed and then it was withdrawn. 















Completed. Phase I/II for multiform glioblastoma.  














Completed: Phase I for adult solid tumour. 
Recruiting. Phase I for advanced refractory solid tumours. 
BAL101553  





















Completed. Phase I for solid tumours.[18]  
Completed. Phase I/II for metastatic colorectal cancer. 
Ongoing. Phase II for metastatic non-small cell lung cancer. 
Completed. Phase II for unresectable hepatocellular carcinoma.[22] 
Ongoing. Phase III for non-squamous, non-small cell lung cancer.[23] 
Completed. Phase II for gastric cancer, refractory multiple myeloma 
Data in this table have been obtained from www.clinicaltrials.gov and when results of the trials have been published, the references are cited.  
 
 
The fact that some CSL are not susceptible to some tumour resistance mechanisms against the taxanes and the Vinca alkaloids, 
such as not being substrates of the multidrug resistance proteins[24] and the discovery of the tumour vascular disrupting activity 
of some of them[25] has renewed interest in the discovery and development of colchicine site drugs. However, some problems 
still remain in their development as successful anticancer agents, mainly owing to their low intrinsic water solubility and 
insufficient potency, which results in the survival of a rim of cancer cells that finally allows tumour to regenerate.[26] In this 
review, we focus on colchicine site agents carrying pyridine rings or related azines and discuss the pharmacokinetic and 
pharmacodynamic consequences associated with their presence. 
The microtubules of eukaryotic cells form part of the cytoskeleton and play a role in cell shape maintenance, form the mitotic 
spindle during mitosis and are also implicated in cell movement, intracellular transport and signal transduction.[27] The main 
constituent of the microtubules are the tubulin αβ heterodimers, GTPases that polymerize along their longitudinal axes to form 
protofilaments that align themselves side by side to form hollow cylinders. The microtubules are dynamic structures that 
preferentially grow at one end (plus end) and shorten at the other (minus end). When growth and shrinkage occur at both ends, 
this is known as a phenomenon called dynamic instability. This event results from the inherent instability of tubulin in the straight 
conformation required to form the microtubules, a high energy state which is also used by other proteins travelling along the 
microtubules.[28] The alteration of the dynamic equilibrium of the microtubules more than the actual modification of the 
polymerization equilibrium between the microtubules and soluble tubulin dimers in cells is considered responsible for the 
biological effects of antimitotic agents acting on tubulin.[29] 
In the absence of structural information at atomic resolution, at least up the 21st century the design of CSL relied heavily on 
structure – activity relationships[30, 31] which have been generalized to multiple scaffolds by means of several pharmacophore 
models.[32-35] The first atomic structure of the tubulin dimers was the electronic crystallographic model of taxol-stabilized zinc-
induced straight sheets formed by anti-parallel protofilaments.[36, 37] This structure corresponds to the straight tubulin found in 
assembled microtubules, but the structure of the curved tubulin dimers targeted by CSL was not deciphered until 2004, when the 
X-ray crystal structures of the complex of two head to tail tubulin dimers in complex with phosphoproteins of the stathmin family 
was resolved.[38] The same strategy allowed the subsequent determination of the structures of tubulin in complex with several 
CSL, including classical CSL carrying trimethoxyphenyl rings, such as DAMA-colchicine (6) (DeAcetylMercaptoAcetyl-
colchicine),[39] podophyllotoxin (4),[39] and colchicine (3) itself[40, 41] and new chemotypes displaying distinct binding modes, 
such as the sulfonamides ABT-751 (11) and T138067 (18),[42] the pyrrolidindione TN16 (14),[42] and the two enantiomeric 
pyridopyridazines NSC 613862 (CI980) (S) (9) and NSC613863 (R) (10).[43] Structure based drug design (SBDD) of CSL began 
with these complexes being resolved at a modest resolution that provided an unprecedented insight into the structural flexibility 
of the colchicine site of tubulin.[44-46] Recently the inclusion of a third component, the tubulin tyrosine ligase in crystal growth 
has improved the achieved resolution in the X-ray refinement,[47, 48] thus providing a better starting point for the SBDD.[32, 
49, 50] 
The X-ray crystal structures of complexes of CSL with tubulin have defined three sequential binding pockets denoted as zones 1 
– 3 (Fig. 2); the first two mainly formed by hydrophobic aminoacids whereas in the third one some polar residues are also 
found.[44, 45] Most of the co - crystallized ligands occupy only two of the adjacent sites, either 1 and 2 or 2 and 3, with ABT751 
(11) being the only one in contact with all of the three sites although it does not fully occupy the three of them. Zone 1 corresponds 
to the binding site for the tropolone (B) ring of colchicine (3) which binds in the interfacial surface between the α and β tubulin 
subunits and binding ligands, therefore, making contact with residues from both subunits. Zone 2 corresponds to the binding 
pocket for the trimethoxyphenyl ring (A) and mostly extends to β tubulin, including cysteine 241β, important for binding, and 
the gate residue Leu255β which open or closes the access to Zone 3 depending on the nature of the resident ligand. Zone 3 is 
more deeply allocated in β tubulin and is lined by several polar residues. Ligands binding at Zones 1 and 2 are not usually 
continuous moieties but consist of two separated moieties (e.g. the A and B rings of combretastatin A-4 (5)) connected by a bridge 
which makes little contact with the protein, as it points toward an open zone in the interfacial region. By contrast, ligands binding 
at Zones 2 and 3 show less clear separation between the binding substructures. 































































































































: Colchicine R = H
6: DAMA - colchicine R = SH
11: ABT-751
9: CI-980 (S) (G2N)













Fig. (2). (A) Schematic representation of the binding of CSL to the site zones. 
   (B) Disposition adopted by known ligands deduced from X-ray structures. 
 
 
2. THE PYRIDINE SCAFFOLD 
 
Pyridine can be considered as the result of replacing one methine (CH) of benzene by a nitrogen atom. Further substitution of the 
methines of pyridine by adding nitrogen atoms generate the azines, many of which are important scaffolds in medicinal chemistry, 
such as  the diazines pyridazine, pyrimidine and pyrazine (Fig. 3).[51-53] The resulting heterocycles are aromatic, but in spite of 
their similar size dramatic changes in properties and reactivity upon addition of increasing numbers of nitrogen atoms and with 
respect to the benzenic analogues result, which have important effects on the medicinal chemistry of the compounds. The 
benzofused pyridines, namely quinoline and isoquinoline and their corresponding aza analogues are also important scaffolds in 
medicinal chemistry, similar to the pteridine present in folic acid.[54] Additional variations involve azines fused to heterocycles 
of different sizes, including systems incorporating the azine nitrogens in the fusion. Furthermore, and in contrast to what is 
 
observed for benzenes, all these heterocyclic systems display a great variety of tautomeric forms depending on the substituents 
introduced on the ring, as evidence the pyridones, thus providing these scaffolds with even more versatility from a medicinal 
chemistry viewpoint. The totally and partially hydrogenated derivatives behave very much like their acyclic counterparts but are 

































Fig. (3). Structure of benzene and of several azines important in medicinal chemistry. 
 
The initial effect of the introduction of a nitrogen atom into pyridine is its basic character, although unsubstituted pyridine with 
a pKa of 5.23 is mostly in its neutral form in water. However, introduction of substituents greatly modify the basicity of the 
system (Fig. 4), and 2- and 4- aminopyridines are expected to be partially and fully protonated in water at physiological pH due 
to their pKas of 6.9 and 9.2, respectively. The introduction of additional nitrogen into the pyridine ring dramatically reduces their 
basicity, and the diazines have pKas of 0.4 for pyrazine, 1.1 for pyrimidine and 2.1 for pyridazine, while the triazines show pKa 
values around 1. On the other hand, the benzofused systems display basicities similar to the non-fused analogues, and pyridine, 
































































Fig. (4). Protonation equilibrium for pyridine and effects of the substituents on the pKa. 
 
The pyridine nitrogen behaves as a hydrogen bond acceptor of medium strength (pKBHX = 1.86),[56] but this value changes 
considerably with substituents, with trends similar to those observed in basicity. Pyrimidine and pyrazine are weaker hydrogen 
bond acceptors while pyridazine and the benzofused systems are of similar strength as pyridine.[57] The protonation of pyridine 
nitrogen turns it into a strong hydrogen bond donor. Therefore, the replacement of phenyl rings by pyridines or other azines can 
provide additional hydrogen bonding interactions. However, the energetic consequences are difficult to ascertain, as stronger 
hydrogen bonding groups also pay higher desolvation penalties.[58] The strong hydrogen bond basicity of pyridines probably 
makes brain penetration more difficult.[59] 
Another important medicinal chemistry property, which experiences substantial variations when going from benzene to pyridine, 
is polarity. Pyridine is highly polar with a dipole moment of 2.2 D, and the pyridine N-oxides are even more polar.[60] The high 
polarity of azines is often used as a means of reducing the lipophilic character and improving water solubility and oral 
absorption.[60, 61]  
Replacement of electron rich aromatic rings with electron deficient azines is also used as a strategy to improve the biological 
stability and reduce the metabolic oxidation of drugs. The hydrogen bond basicity of the pyridine nitrogen also contributes to this 
effect.[57]  
 
3. CLASSIFICATION  
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Compounds included in this review have been classified according to their structure and accommodation into the colchicine site. 
In this respect, the presence of more or less extended bridge connecting two aromatic systems, one of them usually a 
trimethoxyphenyl moiety, is the most general structure of CSL. Nevertheless, many other compounds have been described as 
binding to the colchicine site of tubulin and several of the crystalline structures of their complexes with tubulin have been 
published. Accordingly, we have grouped the pyridine based-ligands in four groups: 1) classical, 2) systems lacking the 
trimethoxyphenyl moiety, 3) quinolones-acridines and 4) polycyclic derivatives. In these groups the pyridine (pyridazine, 
pyrimidine, pyrazine or other azines) can form part of the basic structure or be introduced as a substituent of a core structure 
during SAR studies. 
 
3.1. Classical ligands: 
 
We have included in this large group all of the compounds that contain a trimethoxyphenyl system or highly structurally related 
moiety in an “aromatic ring–bridge–aromatic ring” scaffold. Most of the known CSL belong to this subgroup, as it is the case for 
colchicines, phenstatins, combretastatins and isocombretastatins... According to the zones of the colchicine site,[44, 45] these 
ligands locate the trimethoxyphenyl (A ring) in the Zone 2 of the site, the other ring system (B ring) in Zone 1 and the bridge in 
the space between α and β tubulins. Other compounds included within this group, as those in figures 14 and 15, lack the 
trimethoxyphenyl moiety, but other rings play the role of binding to Zone 2 in similar pose. Several trimethoxyphenyl derivatives 
of polycyclic structure are preferably included within group 3.4. Ligands included within this group do not extend to Zone 3 of 















































6: R=SH DAMA-colchicine 4: Podophyllotoxin 18: T138067  
Fig. (5). Classical ligands of the colchicine site, characterized by the presence of a trimethoxyphenyl moiety or related substructure 
binding to the Zone 2 of the site. 
 
In this group, the pyridine can be present in two of the structural moieties: as a replacement of the ring B system 
(methoxytropolone of colchicine (3), benzodioxole of podophyllotoxin (4) or 3-fluoro-4-methoxyphenyl T138067 (18)),[62] or 
as a replacement of the bridge (Fig.6).[63] Another possibility is to introduce the pyridine as a substituent (for example on the 






























21: Pyridine "substituent"  
Fig. (6). Classical ligands containing pyridine moieties by replacement of the B ring or the bridge of combretastatin A-4 (5) or as substituents 
in podophyllotoxin (4). 
 
3.2. Systems lacking the trimethoxyphenyl moiety 
 
The trimethoxyphenyl moiety is crucial for the binding of a great number of ligands to Zone 2 of the colchicine site. The absence 
of this substructure, or a highly related one, produces lack of the inhibitory activity on the polymerization of the tubulin in many 
types of antimitotic agents. But this is not essential, as there are other structural types of ligands that bind to the site 
accommodating a variety of aromatic systems in Zones 1-3 without the existence of the trimethoxyphenyl or related substructure 
located in Zone 2. 
Among these ligands, those carrying a pyridine present a variety of possibilities and they can be grouped as follows: a) 
sulfonamides and sulfonates with three aromatic moieties, each one being accommodate in different Zones 1-3, b) 
Pyrrolidindiones, pyperidindiones and pyperazinones, c) Pyrido[3,4-b]pyrazines, and d) 2-(2-(pyrid-3-yl)ethenyl)benzothiazole 
and other ligands. The last one is a group that has systems connected by a trans-double bond, a situation that is detrimental for 
the inhibitory activity for the classical ligands, such as the large family of combretastatins.[65]  
The binding mode is different among these groups. For example, sulfonamides such as ABT-751 (11) bind to three zones,[42] a 
fact that has enhanced the knowledge regarding the colchicine site, including Zone 3 which was not previously considered in the 
common pharmacophore.[35] On the contrary, pyridopyrazines, such as K2N (10) and G2N (9) occupy Zones 2 and 3 without 
binding to Zone 1.[43] The representative binding modes of these types of ligands, whose crystalline structure in complex with 



















































































Fig. (7). Types of ligands included in the family characterized by the lack of trimethoxyphenyl moiety or a related substructure. 




In this group compounds, characterized by the presence of two aromatic systems bonded through a bridge, one of the aromatic 
systems being bicyclic (quinolones) or tricyclic (acridines and related), have been included (Fig. 8). This family may well be an 











Fig. (8). Generic structures of quinolones and acridones. 
 
3.4. Polycyclic derivatives and other 
 
The fourth group is a miscellaneous one in which, polycyclic systems unrelated to groups 1-3 and the rest of CSL can be included 
(Fig. 9). For these compounds the binding mode to the colchicine site is not known, except for those with crystalline structures 
















22 17: Plinabulin  
Fig. (9). Structures of representative polycyclic inhibitors of tubulin polymerization. 
 
 
4. PYRIDINE LIGANDS  
 
In this section, pyridine containing CSL described in recent years are reviewed. Some of them are modifications of known ligands, 
whereas others have new skeletons characterized by the presence of the pyridine moiety. These compounds are grouped by the 
structural similarity between them and other readily known, well established, families of CSL. 
 
4.1.  Classical ligands 
 
4.1.1. Colchicine derivatives 
 
The use of colchicine is limited because of its toxicity but it has been used as a prototype to prepare new families of potential 
antitumour drugs with better pharmacological profiles. The acetamido group of thiocolchicine (23) was replaced by pyridine 
carboxylates, and the resulting esters maintained the tubulin inhibitory activity while allowing the aqueous solubility by formation 
of pyridine hydrochloride salts to be improved (Fig. 10).[66] In contrast, colchicines modified at the C ring as hetero Diels-Alder 
adducts with pyridinylnitroso reagents have been prepared as prodrugs  (24) (Fig. 10), with the pyridine rings providing the 
adequate balance of reactivity in the cycloadditions and stability of the cycloadducts as evidenced by cytotoxic potencies similar 
 






























24: DA prodrugsThiocolchicine esters
23: TPI 0.76 µM  
Fig. (10). Colchicine derivatives with pyridine moieties. 
 
4.1.2. Podophyllotoxin derivatives 
 
Podophyllotoxin (4) is an aryltetralin lactone isolated from Podophyllum peltatum and Podophyllum emodi that binds at the 
colchicine site of tubulin causing microtubule disassembly.[10] Semisynthetic work at Sandoz laboratories fueled by the 
conviction that glycosylation would improve the pharmacological properties of lignans led to the discovery of the 4’-
demethylepipodophyllotoxin derivatives etoposide and teniposide, which were thereafter used as anticancer compounds acting 
by a totally different mechanism, as they interfere with the scission-reunion step of mammalian topoisomerase II and cause DNA 
damage.[68] Great efforts, but with limited success, have been devoted to improving the pharmacological properties of 
podophyllotoxin (4), some of them involving the introduction of pyridine rings or related azines (Fig. 11). These changes aimed 
at improving the pharmacokinetics by increasing the water solubility with polar groups or by reducing the stereochemical 
instability of the strained, but important for the activity, trans-trans-cis stereochemistry of the aryltetralin lactone and also the 
pharmacodynamics by introducing potential tubulin interacting centers.  
The enlargement of the B and E phenyl rings of podophyllotoxin (4) as quinoxalines (29) or phenazines (25) has been of limited 
success as they result in poorly soluble or much less potent derivatives, possibly due to both not satisfaction of the hydrogen bond 
acceptors and too much steric bulk, although activities different from tubulin inhibition have arisen as a result.[69, 70] Similar 
results have been observed after the introduction of pyridine esters on the hydroxyl group of podophyllotoxin (4).[64, 71] 
One of the earliest aza-podophyllotoxin examples was the conversion of the aryltetralin lactone into an aryltetrahydroisoquinoline 
cyclic carbamate by substitution of the easily epimerized C2 carbon by a nitrogen atom, thus preventing the inactivation to cis 
lactones of the picropodophyllin series.[72, 73] Despite favorable initial findings, the focus soon turned to dual topoisomerase I 
and II targeting compounds such as azatoxin, although this route seems to have been abandoned.[74] The replacement of both 
the C2 and the C4 carbons by nitrogen results in active compounds with increased stereochemical stability and in vivo activity 
when compared with podophyllotoxin (4).[75] The development of synthetic methodologies towards 4-aza-2,3-
didehydropodophyllotoxin (26, 28) analogues, such as the one-step multicomponent reactions of anilines or heterocyclic amines 
with tetronic acid or related reagents and aldehydes, has enabled fast access to podophyllotoxin-mimetic compounds.[76-78] The 
benzo or heteroaryl fused dihydropyridine scaffold preserves the active conformation of podophyllotoxin, (4) but with less 
troublesome stereochemical centers.[78, 79] Structurally related triazolopyrimidines (30) selected by virtual screening protocols 
have also been shown to possess antitubulin activities.[80] 
 














































































Fig. (11). Podophyllotoxin derivatives with azine modifications. The azines have been highlighted by means of thicker bonds. 
 
4.1.3. Noscapine derivatives 
 
Noscapine (31) is a phthalideisoquinoline alkaloid isolated from Papaver somniferum used as a cough suppressant since mid-
1950s. It has very favourable pharmacokinetic properties[81] as it is rapidly absorbed after oral administration with a 
bioavailability of 30% and a low toxicity profile.[82] It suffers first pass metabolism mainly by breakage of the bond between 
the tetrahydroisoquinoline and the phthalide.[83] Recently, noscapine (31) has been shown to arrest cells at mitosis by inhibiting 
tubulin polymerization, although with moderately weak activity, and has entered clinical testing[84] and many of its derivatives 
have been described and have shown improved activity profiles, thus generating meconine (34) and (hydro)cotamine (35,36).[85, 
86] Noscapine (31) binds weakly and nonspecifically to tubulin at a site different from the colchicine domain but 7-demethoxy-
7-aminonoscapine (33) is a more potent cytotoxic agent acting as a tubulin inhibitor competitive with nocodazole, an established 
colchicine domain binder, but unfortunately suffers from low metabolic stability.(Fig. 12)[87, 88] The formation of carbamates 
or esters at the 7 position of the benzofuranone results in highly potent cytotoxic compounds, presumably acting as prodrugs of 
the parent amine or phenol.[89] Noscapine analogues modified at the 9-position also display potent cytotoxic activity but they 








































TPI > 50 µM
 
Fig. (12). Modifications on the noscapine structure leading to improved cytotoxic potency and main products of hydrolytic metabolism. 
 
 
4.1.4. Combretastatin derivatives  
 
The combretastatins form a family of natural products originally isolated by Pettit et al. from the bark of the South African bush 
willow tree Combretum caffrum, including stilbenes, dihydrostilbenes, phenanthrenes and the biosynthetically unrelated 
macrocyclic lactones known as combretastatins D.[91] The most successful of the combretastatins are the cis stilbenes known as 
combretastatins A, some of which have reached clinical trials for the treatment of diverse types of cancers, as for instance the 
phosphate prodrugs of combretastatin A-4 (5) and combretastatin A1. The parent drugs are TPI acting at the colchicine site of 
tubulin which results in potent cytotoxicity against several cancer cell types and also in vascular disrupting activity.[25] As a 
result of the success story of these natural combretastatins, many synthetic derivatives have been prepared in an attempt to 
overcome some of their main drawbacks: their low aqueous solubility which requires the formation of prodrugs, their chemical 
and metabolic instability due to the easy isomerization of the active cis isomers to the thermodynamically favored but inactive 
trans isomers, and insufficient tumour cell killing potency which results in survival of the malignant cells at the tumour rims with 
eventual regeneration of the tumour mass.[92, 93] The combretastatins are diaryl cis stilbenes and the main structural 
modifications involving the introduction of pyridines or related systems have targeted either aromatic ring and/or the connecting 
bridge. Along with these modifications, new families of related tubulin inhibitory compounds with bridges of different lengths 
have emerged, such as the phenstatins (diarylketones), the isocombretastatins (1,1-diarylethenes), the diarylamines and the 
chalcones.[12, 94] 
 
4.1.4.1 Replacement of the phenyl rings by azines 
 
The 3-hydroxy-4-methoxyphenyl (guaiacol) B ring of combretastatin A-4 (5) and related analogues can be successfully changed 
to a 4-methoxyphenyl ring, a 3-amino-4-methoxyphenyl ring or its amides, naphthyl rings, indole rings linked by several positions 
and even bigger carbazole rings, thus showing that it is its more easily replaced moiety. Replacement of the B-ring of 
deoxycombretastatin A-4 by pyridines or other diazines results in a remarkable increase in solubility at the expense of a mild 
reduction in TPI and cytotoxicity.[62] Further extension to quinolines or quinoxalines have resulted in a preference for the 
nitrogen on the ring not connected to the bridge and a potency reduction for both the combretastatins’[95] and the phenstatins’[96-
98] series, both of them being even slightly less potent than the corresponding naphthalenes.[99-102] Whereas introduction of 
methoxy groups on the quinoline reduced the potency of the resulting derivatives, 5-amino-6-methoxy-2-(3’,4’,5’-
trimethoxybenzoyl)quinoline (38) showed improved TPI when compared with combretastatin A-4 (5) and subnanomolar 
antiproliferative potency.[95] This substitution pattern is reminiscent to that of the active form (AVE-8063 (39)) of ombrabulin, 
an aminocombretastatin prodrug in clinical evaluation.[103] The addition of the quinoline nitrogen not only provides high potency 
but might also improve the solubility so that no solubilizing prodrugs are further required, thus avoiding additional 
complications.[104] Replacement of the amino group by larger moieties or the use of different bridges between the two aromatic 













































Fig. (13). Combretastatin analogues with phenyl rings replaced by azines. 
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Remarkably, in a series of 3-(3’,4’,5’-trimethoxyanilino)benzothiophene-2-carboxylate derivatives with tubulin inhibitory 
potencies and cytotoxic activities similar to that of combretastatin A-4 (5) the introduction of nitrogen atoms on the 
benzothiophene skeleton yielding thieno[2,3-b]pyridines resulted in a substantial potency increase against several tumour cell 
lines.[109] The thieno[2,3-b]pyridine (43) required a tailored synthesis from 2-chloropyridine-3-carbonitrile and a thioglycolate, 
followed by diazotation of the resulting amine and substitution by bromine, previous to the usual Buchwald-type coupling with 
trimethoxyaniline. Related thieno[2,3-c]pyridines (44) and tetrahydro analogues (45)[110, 111] also maintain the high TPI and 





































42: TPI 0.9-1 µM




















45: TPI 0.6 µM
 
Fig. (14). Diarylamine combretastatin analogues with phenyl rings replaced by azines. 
 
In a structurally related series of N-aryl-3,4,5-trimethoxyanilines a quinoline or a methoxypyridine results in significant 
reductions in potency when compared with p-methoxyphenyl rings, naphthalenes, or indoles.[112] This overall different 
behaviour is also reflected on the amino bridge, where methylation is required in order to achieve cytotoxic activity at a nanomolar 
range.  
Within this series of amino methylated diarylanilines SAR elaboration, after a cell- and caspase-based apoptosis high-throughput 
screening (HTS) assay, found that replacement of the trimethoxyphenyl ring by quinazolines results in potent cytotoxic 
compounds,[113, 114] which led to the discovery of Azixa (Verubulin) (41), now in phase II clinical trials.[13, 17, 114-116] In a 
related study, replacement of the trimethoxyphenyl ring by 3,6-disubstituted pyridines results in compounds that are only 
cytotoxic at micromolar concentrations[117] and even less potent when the bridge is an NH group or an oxygen atom.[118] 
However, cyclization of the aniline nitrogen to one of the aromatic rings to form a tetrahydroquinoline increases the potency 
tenfold and one hundred to one thousand fold when quinazolines become the substituting aryl ring on the nitrogen.[119, 120] 
Further substitution of the quinazoline by different quinolines, isoquinolines or purines do not improve the activity profile but 
the physicochemical properties can be substantially improved upon by the chemical modification of the quinazoline 2 substituent 
(42).[121] 
In a related approach of substitution of the phenyl rings of known CSL by pyridine analogues (Fig. 15) and based on the model 
microtubule destabilizer chalcone MDL-27048 (47)[122] natural products (as for example 46) were selected from a 
pharmacophore search[123] or synthesized as cyclopropylcarboxamide analogues, (48)[124] but in both instances only weak 
potencies were observed. Similarly, incorporation of pyridine rings on 1,2,4-oxadiazole and related scaffolds[125-129] results in 





















Fig. (15). Chalcone analogues with phenyl rings replaced by pyridines. 
 
4.1.4.2 Pyridine as a replacement of the bridge 
 
Soon after the discovery of the combretastatins the cis double bond emerged as a site that could be used for improvements due to 
its metabolic and chemical isomerization to the biologically inactive trans isomers.[130] As a result, a large number of analogues 
of 1,2- or 1,3-diaryl five- or six- membered carbocyclic or heterocyclic rings (49), larger systems such as the benzofused ones, 
and others such as those with the bridge cyclized onto one of the pending aromatic rings have been prepared and assayed. As a 
result, compounds with not only high configurational stability but also with enhanced potency and water solubility have been 
obtained.[58, 91, 92, 131, 132] 
The first combretastatin analogues with aromatic azine bridges kept the aryl substituents at contiguous positions of either 
pyridines[63] or pyrimidines or pyrazines.[101, 133] The resulting pyridines and diazines (49) were more potent than the 
corresponding (inactive) phenyl derivatives [131] but much less so than the original stilbenes or analogues with five membered 
rings.[63, 132] For these pyridine analogues higher potency was observed when the pyridine nitrogen was closer to the 
trimethoxyphenyl ring than when it pointed in the opposite direction (Fig. 16). Larger systems such as pyridopyrazines, and 
quinoxalines caused a drastic reduction in potency, which when combined with similar results obtained for other benzofused 
systems, such as the indoles, led to the conclusion that there was a limited available space in tubulin for the bridge.[63, 132] 
Structural information and further structure – activity studies point to a more severe restriction in terms of protrusion out of the 
plane of ring B, as would be the case for the aromatic systems considered here, rather than an actual steric limitation.[58, 134] In 
































50: TPI= 0.79 µM
 
Fig. (16). Combretastatin analogues with azine bridges. 
 
The association of combinatorial synthesis of focused chemical libraries with the pharmacological testing of the synthesized 
compounds is a powerful technique for the discovery of novel scaffolds deploying biological activities. A combinatorial synthesis 
of a 2,4,5-substituted pyrimidine library using a sequential three-component, one-pot reaction between a iodochromone, an 
arylboronic acid, and an amidine followed by its assay for the inhibition of the human hepatocellular carcinoma cell line 
uncovered 2-methyl-4,5-diarylpyrimidines as a new active scaffold with micromolar potency.[136] Subsequent SAR optimization 
of the substituents of the positions 2 and 5 of the pyrimidine led to the discovery of 2-amino-4,5-diarylpyrimidines (50) as potent 
inhibitors of tubulin polymerization through binding at the colchicine site and potent cytotoxic compounds. (Fig. 16)[137, 138]  
Azines with two aryl substituents on non-contiguous (e.g. 2,6-diarylpyridines) atoms have also been synthesized as 
configurationally locked colchicine site inhibitors based on chalcones. (Fig. 17) 4,6-diarylthioxopyrimidines analogues (56) were 
prepared by condensation of appropriately substituted chalcones with thiourea in refluxing methanol and the resulting compounds 
were shown to possess improved water solubility but mild cytotoxic potency.[12, 94, 139, 140] Following a similar rationale, 
2,6-diarylpyridines (52) were synthesized and shown to be highly potent cytotoxic, vascular disrupting, and tubulin inhibitory 
compounds with improved bioavailability with respect to combretastatin A-4 (5) after oral administration to mice.[141] As 
indicated above for the contiguous diaryl substitutions on large aromatic systems, attempts to fix the double bond configuration 
of antimitotic chalcones by construction of imidazo[1,2-a]-pyridine/pyrazines (53, 54) using a multicomponent Ugi type multi-
component reaction and replacement by an amino group[142] or altogether removal of the carbonyl (55)[143] to allow a good 
disposition of the pendant trimethoxyphenyl group disposition of the aromatic rings resulted in a potency reduction compared to 
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Fig. (17). Chalcone analogues with azine bridges. 
 
The incessant search for new CSL with improved pharmacodynamic, pharmacokinetic, and toxicity profiles has led to the 
discovery of novel scaffolds which in turn have resorted to the incorporation of azines as a way of optimizing their properties. 
Thus, due to the biological lability of the ester moiety of 3-(3,4,5-trimethoxyphenylsulfanyl)indole-2-carboxylates (60) (a.k.a. 
arylthioindoles) or related aroylindoles,[144-148] the carboxylates have been replaced by azoles, pyridines and other heterocycles 
with great success. Several of the resulting compounds are more potent than combretastatin A-4 (5) as TPI and cytotoxic 
compounds against human cancer cell lines including multidrug - resistant (MDR) ones, but also showed improved water 
solubility, stability against human liver microsomal enzymes, and intestinal permeability in model assays, with pyridines only 
surpassed by the imidazole and triazole analogues.[129, 149, 150] The 4-substituted methoxybenzoyl-aryl-thiazoles (SMARTs 
(57)),[129] 2-aryl-4-benzoylimidazoles (ABIs (58)),[150] and phenyl-amino-thiazoles (PATs (59))[149] are potent anticancer 
agents targeting tubulin by binding to the colchicine which are rapidly metabolized at the trimethoxyphenyl ring or at the ketone 
by liver microsomal enzymes, thus reducing their bioavailability. Ring fusion of the carbonyl into the azole by formation of the 
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4.2. Systems lacking the trimethoxyphenyl moiety 
 
As the number of ligands binding at the colchicine site of tubulin but lacking the trimethoxyphenyl ring of colchicine (3), 
podophyllotoxin (4) and combretastatins started to steadily increase, it became apparent that it could be replaced by several other 
groups, often incorporating azines or related ring systems.[12, 94] Along with this finding, a new binding zone (Zone C) in the 
colchicine site of tubulin sitting deeper in the β-tubulin subunit and not being occupied by the ligands carrying the 
trimethoxyphenyl ring was uncovered for some of these chemical skeletons.[44, 45] When the trimethoxyphenyl ring is present 
Leu255β closes the access to this pocket, but with less bulky moieties it adopts a different conformation which uncovers a groove 
lined by several polar groups.[44] This polar cavity has also been occupied by several substituted azines thus increasing the 
polarity and the aqueous solubility of such ligands and providing improved pharmacokinetics.[32, 43] 
 
4.2.1. Sulfonamides and sulfonates 
 
The sulfonamide group (-SO2-NH-) is present in many clinically useful drugs with antibacterial, diuretic, hypoglycemic, anti-
thyroid, anti-inflammatory, antihypertensive, anti-parasitic and antitumour activities, amongst others.[152-154] These actions are 
mediated by interactions with many different targets, and anticancer activities have been described for sulfonamides acting on 
carbonic anhydrases, histone deacetylases, the NF-kB, matrix metalloproteases, tubulin, and many other targets. 
Taking into account the privileged structure of sulfonamide drugs that provides orally active drugs with a manifold of biological 
activities,[155] researchers from the Japanese Eisai Company discovered in the early nineties the sulfonamide ABT-751 as an 
orally bioavailable non MDR substrate[156] antimitotic drug with antitumour activity against solid tumours,[157] which was 
later acquired by Abbott Labs and renamed ABT-751 (11). The pyridine ring of ABT-751 (11) is important for a good oral 
efficacy in the sulfonamide series[155, 156] but surprisingly, for sulfonate analogues of ABT-751, the pyridine nitrogen causes 
a drastic potency reduction compared to the phenyl analogues.[158-163] Unfortunately, so far clinical trials for ABT-751 (11) 
suggest that it is not sufficiently potent to warrant further development,[18, 19, 164] but its oral bioavailability, an acceptable 
toxicity profile and its insensitivity to multidrug resistance pumps (MDR) justify recent research aimed at finding more potent 
analogues of ABT-751. The X-ray crystal structure of ABT-751 (11) in complex with tubulin[42] showed a previously 
unpredictable binding mode which for the first time confirmed that the pyridine ring acts as a replacement of the trimethoxyphenyl 
ring and partially uncovered the new binding zone in the colchicine site. This structure provided a rationale for the binding of 
related structures to tubulin and explained the important role played by the pyridine nitrogen on the potency of ABT-751 (11) 
against xenograft models when compared to phenyl analogues.  
The recognition of the structural equivalence of the pyridine ring of ABT-751 (11) and the trimethoxyphenyl ring of 
combretastatin A-4 (5) when bound to tubulin led to the synthesis of hybrid molecules with a sulfonamide linker connecting a 
carbazole ring (deemed as an expanded B ring) and a trimethoxyphenyl ring (62) (Fig. 19).[165] The resulting hybrid molecule 
(62) presented antiproliferative activity in vitro and in vivo antitumour effectiveness, an activity surprisingly not due to inhibition 
of tubulin polymerization. Further elaboration of the hypothesis led to sulfonamide IG-105 (63) by the replacement of the 3,4,5-
trimethoxyaniline with a 2,6-dimethoxypyridin-3-amine, which strongly inhibited tubulin polymerization and showed a potent 
activity against human leukemia and solid tumours in vitro and in vivo.[166, 167] The potency of the 2,6-dimethoxy-3-pyridyl 
moiety seems to be confined to the sulfonamides as it inclusion in combretastatin analogues results in a significant potency 
reduction.[167] The chameleonic nature of the sulfonamide group showed up in other structurally related sulfonamides acting on 
targets different from tubulin, such as for instance indisulam (64)[168] or the Polo-like Kinase inhibitors HMN-176 (66) and its 
prodrug HMN-214 (65).[169] 
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Fig. (19). Rationale for the design of combretastatin A-4 (5) and ABT-751 (11) hybrids and structures of the related non tubulin 
inhibitors HMN-176 (66), its prodrug HMN-214 (65) and indisulam (64). 
The formation of an additional cycle incorporating the sulfonamide nitrogen and the pyridine ring of ABT-751 (11) has also led 
to conformationally restricted analogues with increased anti-tubulin potency (Fig. 20). A pyridine nitrogen is favored in the new 
A rings when the additional ring is either aromatic (indole[170] and 6-azaindole[171] analogues (68-75)) but partially reduced 
indoline[170, 172] analogues are also very potent. For these conformationally restricted analogues of ABT-751 (11), the aniline 
substituent directed towards the deep groove in β tubulin can be efficiently replaced by a 3- or 4-pyridyl[172] or 
isonicotinamido[170] substituent or even the corresponding N-oxide.[173] In a related strategy, ABT-751 (11) has been cyclized 
to benzopyridothiadiazepine (67)[174] and benzopyridooxathiazepine [175] derivatives with a pendant phenethyl group and a 
substantial potency reduction was observed. Although moving the phenethyl substituent to the pyridine nitrogen with concomitant 
double bond reorganization and ring substitutions led again to highly potent inhibitors of tubulin polymerization. In vitro stability 
studies on this new class of sulfonamide and sulfonate analogues suggest that their chemical and metabolic stability are sufficient 



































Fig. (20). Design of conformationally restricted analogues of ABT-751 (11) and successful pyridine substituents occupying the 
zone 3.  
In the sulfonamide series the pyridine A ring has proven important for the achievement of oral bioavailability, probably due to 
its high polarity. The diaminopyridines are expected to be basic centers, but the impact of protonation on tubulin binding seems 
to be limited, as systems with reduced basicity, such as the azaindoles or even lacking it as the indoles or the phenyl analogues, 
are still potent cytotoxic and tubulin polymerization inhibitory compounds.[179] 
 
4.2.2. Pyrrolidinediones and piperazindiones 
 
Since the discovery of phenylahistin (76) and plinabulin (17) (Fig. 21) in the late nineties,[180-183] the diketopyperazines (DKP) 
have been developed as a new family of antitubulin agents, binding at the colchicine site. These compounds are moderately potent 
in comparison with reference combretastatin A-4 (5), but recently the coupling of the benzophenone[184] moiety to the DKP has 
increased the potency of these compounds and the structure activity relationships demonstrated that a 2-pyridyl ring bonded to 
the DKP is highly convenient for the activity (78). The benzophenone can also be replaced by a pyridine. For all of them, a 
 
hydrogen bond between de pyridine type Nitrogen and the DKP NH (reversed in TN-16 (14)), flattening the structure in this part 
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Fig. (21). Structures of (-)-phenylahistin (76) and related plinabulin (17) and azine derivatives. The structure of the 
pyrrolidindione TN-16 (14) is shown for comparison. 
 
Recently, the structure of plinabulin (17) when in complex with tubulin has been solved, and the structural resemblance with TN-
16 (14)[42] as well as the establishment of the intramolecular hydrogen bond has been confirmed, therefore unveiling the 





Originally conceived as deaza methotrexate analogues, it soon became clear that the pyrido[3,4-b]pyrazines lacked antifolic 
activity and were instead antimitotic agents acting on the colchicine site of tubulin.[186] Structure-activity relationship studies 
indicated that the basic diaminopyridine is an essential structural requirement.[187, 188] The fused dihydropyrazine increases the 
pyridine basicity and tolerates diverse substituents in positions 2 and 3.[189] 
Clinical trials with mivobulin (CI-980) showed that it lacks sufficient activity in the treatment of disseminated malignant 
melanoma [190] metastatic colorectal carcinoma[191] progressive malignant gliomas[192] and soft tissue sarcomas.[193] 
The X-ray crystal structure of tubulin in complex with mivobulin and its enantiomer[43] provided an explanation for the observed 
structure – activity relationships. The dihydropyrazine and the 3-substituent occupy the pocket of the trimethoxyphenyl A ring 
and the protonated diaminopyridine forms a salt bridge with Glu200β, thus explaining the significance of the basic pyridine 
nitrogen. 
 
4.2.4. Quinolones and acridones 
 
The 2-phenylquinolones were initially synthesized as aza analogues of antitumour flavones (Fig. 22), and found to possess potent 
cytotoxicity against colon and lung cancer cells by exerting antimitotic effect through the interaction with the colchicine site of 
tubulin.[194] Their synthesis and biological activity has been recently reviewed,[195] and only the impact of the modifications 
on the biological activity will be discussed here. The basic pharmacophore of this family of colchicine site binders is an (aza)-2-
phenyl-1H-quinolin-4-one, as evidence potent analogues without the optional nitrogen, such as the phenylquinolinones,[196, 
197] as well as with it such as the phenylnaphthiridinones,[198, 199] and the phenylquinazolinones.[200] Interestingly, the 
reduction of the 2-3 double bond results in more potent compounds, with the S enantiomer being the eutomer.[195, 201] With 
respect to the decoration on the pharmacophore, a 6,7-methylenedioxy or methoxy, halogens and amines (e.g. pyrrolidin-1-yl) 
substituents at the 6 position[196, 202, 203] and methoxy groups[196, 197] or fluorine atoms[204, 205] at the 3’ position of the 
pendant phenyl ring provide the best results. The basic pharmacophore has also been extended by bioisosteric replacements of 
the 2-phenyl ring that also lead to potent analogues, with the 2-benzothiazole ring providing optimal results.[206, 207] Recently, 
the skeleton has been further modified by fused pyrrole rings giving the phenylpyrroloquinolones, which endow high tubulin 
binding potencies when the pyrrole nitrogen is substituted with small hydrophobic groups. The phenylpyrroloquinolones are 
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potent TPI but additional mechanisms are also operative, such as inhibition of the aromatase for the pyrrolo[2,3-
h]quinolinones[208, 209] and kinase inhibition for the pyrrolo[3,2-f]quinolinones.[210-212] This manifold mechanistic 








































Fig. (22). Generic structures of quinolone inhibitors of tubulin polymerization. 
 
 
The most potent cytotoxic agents of the different series have been assayed in mice models but neither the quinolones[203, 214] 
nor their aza-analogues[216] provide enough aqueous solubility for oral dosing studies. Therefore, an unprecedented prodrug 
formation on the quinolone, i.e. the formation of a phosphate ester on the tautomeric hydroxyquinoline, has allowed p.o. 
administration with fast regeneration of the active species after absorption.[203] Notably, the effect of the prodrug after oral 
administration mirrored the antitumour effect of the same intraperitoneal dose of the active compound and the compound showed 
a promising safety profile. More conventional prodrug approaches implying the formation of sodium phosphates on phenolic 
hydroxyl groups have also been attempted.[214]  
Modification of the basic flavone pharmacophore by translation of the 2-phenyl ring, such as in the 4-phenylquinolin-2(1H)-ones, 
leads to aza-podophyllotoxin analogues with much less potent cytotoxic activity,[217] but elongation of the linker to the quinoline 
has resulted again in nanomolar cytotoxic compounds.[218] Structurally related acridones with pendant phenethyl substituent 




4.3. Polycyclic derivatives and other 
 
The first example of polycyclic derivatives is CYT997 (79), whose structure contains pyridyl and pyrimidyl residues. 
Screening of Cytopia´s compound library against DU145 and PC3 cancer cell lines followed by exhaustive SAR optimization  of 
the initial hits led to the discovery of CYT997 (79) (Fig. 23),[220] which is actually in phase II clinical trials for the treatment of 
glioblastoma and multiple myeloma because it is able to depolymerize microtubules, it presents cytotoxicity mediated by caspases 
and PI3K AKt/mTOr and it also shows activity as vascular disrupting agent.[221-224]  
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Fig. (23). Structural optimization strategies towards CYT997 (79). 
 
 
Recently, the X-ray crystal structure of CYT997 (79) in complex with tubulin has been resolved. The structure shows a completely 
novel arrangement of the structural elements with respect to previous structures, with the methoxyphenylurea substituting for the 
trimethoxyphenyl ring and with the aminopyrimidine and the pyridine occupying the intermediate region corresponding to the 
tetrahydrocycloheptane ring of colchicine and the propyl extending towards the tropolone – binding zone.  
The azine systems can also be integrated in polycyclic ligands of the colchicine site in different ways, as a central ring with 
pending substituents or as substituents of other central structures. 
Starting from indole derivatives,[225] designed as ligands of hormone receptors but also showing antimitotic effects by inhibition 
of cell cycle at G2/M, a family of polycyclic systems based on indole and pyridine was developed (Fig. 24). For these compounds, 
that are inhibitors of tubulin polymerization by colchicine competitive binding, the unsubstituted indole is required for the 
activity, but the requirement of the pyridine ring is not demonstrated because most of them contain the pyridine and the few 
exceptions are also as potent as pyridine containing representatives. Docking studies of these compounds point to binding in a 
site overlapping the GTP and the colchicine sites and do not justify the requirement of the pyridine system. Among these 
compounds, the sulfonamide LP-261 (81) administered orally has demonstrated its efficacy in vivo and used in combination with 
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Fig. (24). 3-indol-5-yl-1-pyridylbenzenes. 
 
Several compound families characterized by linear extended polycyclic structures with one or two central heterocycles (for most 
of them two azoles), and with two ending moieties deemed to occupy zones 1 and 2. Such end rings can be a benzodioxole and a 
trimethoxyphenyl ring respectively, as those of podophyllotoxin (4) but also more divergent modifications (e.g. pyridines at both 
ends) have been assayed (families I – IV in Fig. 25). As there is no structural information available and they are rather flexible 
systems, they might accommodate themselves in diverse dispositions in the colchicine site, as suggested by docking results and 
therefore the indicated correspondences are only tentative.  
 














































































Fig. (25). Representative structures of several families of extended polycyclic inhibitors of tubulin polymerization and 
proposed binding modes at the colchicine site. 
 
The 1-(3-pyridylmethyl)triazoles (I (83) in Fig. 25) were synthesized by click chemistry as a focused chemical library and are 
moderately active as cytotoxic agents, inhibitors of tubulin polymerization and other typical effects caused by potent ligands of 
the colchicine site, in accordance with a poor accommodation of these compounds in the site, placing the trimethoxyphenyl ring 
in Zone 2 and the rest of the chain and ring in the space between tubulin subunits. [227] The structurally related amides of family 
II (84) were designed as a combination in an unique structure of the cytotoxic ABT-751 and nicotinamides using 1,2,3-
triazoles.[228] Some of them demonstrated to be moderately cytotoxic (in the micromolar range) but potent TPI, displaying the 
characteristic effects of CSL.  
Family III (85) based on the 1,3,5-oxadiazole motif has been tested in the Sea Urchin Embryo Assay and the most potent 
derivatives have a 4-pyridylmethyl substituent at the amino group, showing higher potency in cell cycle arrest in G2/M and TPI 
than nocodazole. Docking studies placed the 4-aminophenyl derivative in the colchicine site, occupying Zone 2 with the 
benzodioxane ring and placing the intermediate azoles in the inter dimer zone and the aminopyridine in Zone 1 (Fig. 25).[229]  
Family IV (86-89) of nicotinic acid derivatives (Fig. 26) with polycyclic structures carrying a triazole or oxadiazole ring have 
been synthesized and assayed,[230, 231] as well as less active families of related oxadiazole compounds.[232] Many structural 
variations have been introduced and some conclusions were drawn, as the convenience of the nicotinic Nitrogen ortho to the 
amino substituent, the detrimental effect of alkylation of triazole Nitrogen or the increase in activity introduced by the 
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Fig. (26). Representative structures of family IV of extended polycyclic inhibitors of tubulin polymerization and 
proposed binding modes at the colchicine site. 
 
Pyridine is part of the fused imidazo[1,2-a]pyridine scaffold (Fig. 27) of a new family of antimitotic agents lacking the 
trimethoxyphenyl ring and other common structural characteristics of CSL.[233-237] This scaffold was investigated as a 
modification of the previously discovered 6H-pyrido[2’,1’:2,3]imidazo[4,5-c]isoquinolin-5(6H)-ones (90). The biological assays 
demonstrated binding to the colchicine site but the in vivo studies were limited by the low water solubility and by the toxicity. 
For MT119 (90), docking studies show the pyrido-imidazole plane lying in the plane A of the pharmacophore (Zone 2), the 
methoxyphenyl ring in the Zone 1, extending the 3-pyridylmethyl ring close to the acetamide of colchicine towards the interfacial 
tubulin space. Other structurally related fused tetrahydroisoquinoline system were also found starting from cytostatic 





































The colchicine site of tubulin is a promising target for the development of antimitotic agents with antitumour, anti-parasitic, anti-
fungal, herbicidal and other biological activities. Unlike tubulin ligands binding at the taxane or vinca sites of tubulin, no CSL 
have reached the market yet, but many of them are in clinical trials. The discovery of their vascular disrupting activity against 
tumour neo-vasculature often at much lower concentrations than their maximal tolerated dose has shifted the focus from the direct 
cytotoxicity against tumour cells, and many of them are often classified as VDA (vascular disrupting agents).[239, 240] However, 
it has also been shown that shutting down the tumour neo-vasculature results in the death of the cells of the inner mass of the 
tumour, but a peripheral rim of survivor cells are responsible for rapid tumour regrowth.[92] Therefore, VDA are often combined 
with more cytotoxic drugs (as for instance paclitaxel) aimed at killing these cells at the periphery. Most of the failures documented 
so far have been attributed to a lack of efficacy and therefore more potent and less susceptible to resistance CSL with improved 
pharmacokinetic properties are actively being pursued. The combination of multiple activities in single chemical entities (the so 
called multiple drugs) is also emerging as an attractive target in some therapeutic areas, in particular cancer chemotherapy. 
In order to improve the existing arsenal of CSL and select the optimal candidates for continuing studies, adequate comparisons 
between drugs is necessary. However, this comparison is often difficult, as there is a great diversity of experimental conditions 
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and assays reported depending on the laboratory and even within the same laboratory. Just to mention a few, TPI activities are 
not always reported and when it is done varying concentrations of tubulin, different buffer conditions, tubulins purified to a 
different degree, and diverse measuring methods are commonplace. Furthermore, in many families of CSL the TPI potency does 
not always correlate with cytotoxicity, different relationships in TPI and cytotoxicity potencies are observed for different families 
of compounds and, in some cases, cytotoxicity varies a lot depending on the cell lines and time lapses used for the studies. These 
variations suggest, in some cases, multiple mechanisms of action and in others, a resistance which can have multiple origins, as 
for instance, reduced drug intake, different tubulins or augmented drug metabolism. In turn, the predictive value of in vitro 
cytotoxicity and even of in vivo animal models for clinical outcome is less than optimal, thus complicating the decision making. 
The highly hydrophobic nature of the colchicine site of tubulin has led in many cases to highly lipophilic and low water soluble 
compounds which often required the formation of prodrugs in order to improve their pharmacokinetic properties and allow 
clinical use (e.g. fosbretabulin).[14] These prodrugs are usually inactive compounds and highly hydrophilic and require activation 
in order to enter the tumour cells and kill them, thus providing the tumours with a means of evading their cytotoxic effects. Other 
families of more hydrophilic nature have allowed even p.o. administration but at the expense of showing lower anti-tubulin and 
cytotoxic potencies, which in some cases has resulted in lack of activity in the clinic (e.g. CI-980).[241] The introduction of 
azines as alternative scaffolds to the benzenic tubulin inhibitors has in many cases improved their pharmacokinetics and in some 
cases enhanced potency (pharmacodynamics) but very seldom have both gains been simultaneously achieved, thus providing a 
great room for improvement.  
The realization that there are three distinct zones in the colchicine site has shown that most drugs occupy only two of them.[44, 
45] Although, we are still far from completely understanding the effects of filling either zone, zone 1 is mainly hydrophobic and 
the most potent ligands are usually bound within it while zone 3 is more polar and enables more soluble ligands but often with 
lower atom binding efficiency. Zone 2 admits both kinds of moieties. To date, the majority of described successful azines bind 
at sites 2 and 3. Therefore, the discovery of new scaffolds or the combination of structural motifs of different families will be a 
means of combining the beneficial effects of all of them.  
An additional area of improvement for CSLs involves the incorporation of different activities in the same molecule (multiple 
drugs). CSL with topoisomerase (e.g. azatoxin),[242] histone deacetylase (HDAC),[243] Hsp 27,[244] CDK4,[245, 246] or 
different kinases (e.g. MEK [247] or VEGFR-2 [210, 248]) inhibitory activity are emerging. In this regard, azines are often found 
in kinase inhibitors, thus providing an opportunity for design of new dual drugs, such as tivantinib. 
The achieved successes and the new design opportunities uncovered guarantee further development in this field, as novel chemical 
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